Bambusa Prices Upsized Immunology IPO

Company Bambusa Therapeutics Event Type Upsized initial public offering priced Modality Long-acting bispecific antibodies Asset BBT001 (IL-4Rα/IL-31); BBT002 (IL-4Rα/IL-5) Target IL-4Rα; IL-31; IL-5 Disease Area Atopic dermatitis; chronic spontaneous urticaria; respiratory Type 2 disease Summary Bambusa Therapeutics priced an upsized US initial public offering on…